BackgroundCheck.run
Search For

Brooke K Schumm, 692813 Thornbrook Rd, Ellicott City, MD 21042

Known as:
Brooke S Schumm Brooke Schuman Brooke Schunm Brooke D
Related to:
Madison R Schumm 27

Brooke Schumm Phones & Addresses

Ellicott City, MD   

Tampa, FL   

4901 Wetheredsville Rd, Gwynn Oak, MD 21207    410-4484731   

Baltimore, MD   

2813 Thornbrook Rd, Ellicott City, MD 21042    410-9136553   

Work

Position: Legal Professional

Education

Degree: Associate degree or higher

Emails

b***[email protected]
Get Report
Control this profile

Mentions for Brooke K Schumm

Brooke Schumm resumes & CV records

Resumes

Brooke Schumm Photo 12

President And Principal

Location:
2624 Queensland Dr, Ellicott City, MD 21042
Industry:
Law Practice
Work:
Daneker Mcintire Schumm Prince Manning & Widmann P.c May 1995 - Nov 13, 2016
President and Principal Semmes, Bowen & Semmes Apr 1, 1991 - Apr 1, 1995
Partner Miles & Stockbridge P.c. Sep 1986 - Mar 1991
Associate Counsel
Education:
University of Michigan Law School 1977 - 1980
Doctor of Jurisprudence, Doctorates, Law Cornell University 1974 - 1977
Bachelors, Bachelor of Science, Engineering
Skills:
Corporate Law, Bankruptcy, Intellectual Property, Legal Writing, Legal Research, Outside General Counsel, Trade Secrets, Appeals, Patents, Trademarks, Joint Ventures, Commercial Litigation, Civil Litigation, Litigation, Arbitration, Trials, Courts, Bankruptcy and Corporate Reorganization, Patent Law, Corporate Transactions, Trademark Law
Languages:
English
French
Spanish
Brooke Schumm Photo 13

President

Location:
Ellicott City, MD
Industry:
Consumer Electronics
Work:
Eagle Cliffs
President Energizer 1962 - 1989
Senior Technology Associate Us Army Jun 1953 - Jul 1983
Col Usa-Ret Eastman Kodak Jun 1953 - Oct 1953
Engineer
Education:
University of Rochester 1958 - 1962
Doctorates, Doctor of Philosophy, Chemical Engineering University of Rochester, Ny 1958 - 1962
Master of Science, Doctorates, Masters, Doctor of Philosophy, Chemical Engineering, Statistics Rensselaer Polytechnic Institute 1949 - 1953
Skills:
Six Sigma, Manufacturing, Cross Functional Team Leadership, Strategic Planning, Engineering Management
Interests:
Social Services
Investing
New Technologies
Battery Engineering and Technology
Travel
Languages:
French
Russian
Portuguese
German
Brooke Schumm Photo 14

Brooke Schumm

Publications & IP owners

Us Patents

Combination And Method Of Treatment Of Cancer Utilizing A Cox-2 Inhibitor And A 3-Hydroxy-3-Methylglutaryl-Coenzyme-A (Hmg-Coa) Reductase Inhibitor

US Patent:
2002008, Jul 4, 2002
Filed:
Jul 25, 2001
Appl. No.:
09/912703
Inventors:
George Kindness - Middletown OH, US
Brooke Schumm - Ellicott City MD, US
F. Guilford - Palo Alto CA, US
International Classification:
A61K031/415
A61K031/366
A61K031/22
A61K031/198
US Classification:
514/403000, 514/460000, 514/548000, 514/562000
Abstract:
The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as “HMG-CoA inhibitor(s)”), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristic of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.

Combination And Method Of Treatment Of Cancer Utilizing A Cox-2 Inhibitor And A 3-Hydroxy-3-Methylglutaryl-Coenzyme-A (Hmg-Coa) Reductase Inhibitor

US Patent:
2002013, Sep 19, 2002
Filed:
Nov 17, 2001
Appl. No.:
09/997490
Inventors:
George Kindness - Middletown OH, US
Brooke Schumm - Ellicott City MD, US
F. Guilford - Palo Alto CA, US
International Classification:
A61K031/7048
A61K031/665
A61K031/415
A61K031/401
A61K031/366
A61K031/352
US Classification:
514/027000, 514/406000, 514/100000, 514/456000, 514/423000, 514/460000, 514/547000
Abstract:
The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as “HMG-CoA inhibitor(s)”), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. Also contemplated is the addition of lipoic acid and compounds to maintain adequate levels of Selenium, Vitamin C and Vitamin E. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristic of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.

Inflammatory Mechanism Modulator Composition And Methods With Anti-Asthmatic Properties

US Patent:
2002013, Sep 26, 2002
Filed:
Mar 26, 2002
Appl. No.:
10/106625
Inventors:
George Kindness - Middletown OH, US
Brooke Schumm - Ellicott City MD, US
F. Timothy Guilford - Palo Alto CA, US
International Classification:
A61K031/496
A61K031/47
A61K031/433
A61K031/417
A61K031/341
A61K031/198
US Classification:
514/400000, 514/362000, 514/255040, 514/311000, 514/562000
Abstract:
The invention proposes the use of a leukotriene antagonist, particularly a montelukast sodium compound such as SINGULAIR, in combination with cystine to combat inflammatory disease and hopefully reduce the necessary use of SINGULAIR. Combination with other anti-inflammatory agents and anti-asthmatic agents is proposed. Selenium to assure glutathione pathway benefit is suggested. The addition of a selective COX-2 inhibitor is suggested.

Rotary Vane Pump With Continuous Fiber Reinforced Polymeric Composite Vanes Less Prone To Catastrophic Failure

US Patent:
2002014, Oct 3, 2002
Filed:
Mar 20, 2002
Appl. No.:
10/102078
Inventors:
Kevin Kirtley - Clifton Park NY, US
Brooke Schumm - Ellicott City MD, US
David Manner - San Jose CA, US
International Classification:
F04C002/344
US Classification:
418/152000, 418/178000, 418/236000
Abstract:
A rotary paddle pump with sliding vanes and stationary side plates fabricated from a continuous carbon-fiber reinforced polymeric material, particularly polyetheretherketone (PEEK), polyetherketoneketone (PEKK), or polyphenylene sulphides (PPS) material yields characteristics of self-lubrication for dry operation, low wear for long life, and high flexural and tensile strength for superior resistance to foreign object damage. Other parts manufactured from continuous carbon-fiber reinforced polymeric composite may be alternately substituted to provide self-lubrication and low wear on surfaces moving relative to each other.

Mobile Outrigger Scaffolding System

US Patent:
2002016, Nov 14, 2002
Filed:
Dec 26, 2000
Appl. No.:
09/747648
Inventors:
Terry Cogar - Prince Frederick MD, US
Brooke Schumm - Ellicott City MD, US
International Classification:
B23B003/04
B23B005/14
US Classification:
182/082000
Abstract:
This invention contemplates a combination and method involving mounting specially designed plates and/or mounting apparatus against and on the standard vertical column used in construction of office structures or other structures including bridges. The plates have a clamping mechanism designed to fit around or on the vertical column. A lower and upper plate are mounted. The plates have a protrusions onto which are mounted a bracket with holes fitting on the protrusions. The bracket is secured with a cotter pin. The brackets project outside the eventual skin of a building and deck planks or pics can be mounted on the brackets. The mobile outrigger scaffolding system allows workmen to safely walk and work on the deck planks to perform work on a floor-by-floor basis. The system can be dissembled quickly and moved to another part of the same floor, to a new floor, and can be used around the outside corner of a structure or from an overhang or from a horizontal beam. The invention is uniquely designed for steel tube construction. A small part of fireproofing can be removed, the invention utilized and the fireproofing replaced.

Combination And Method Of Treatment Of Cancer Utilizing A Cox-2 Inhibitor And An Hmg-Coa Inhibitor And Cystine To Enhance Glutathione

US Patent:
2002016, Nov 14, 2002
Filed:
Jan 26, 2002
Appl. No.:
10/057511
Inventors:
George Kindness - Middletown OH, US
Brooke Schumm - Ellicott City MD, US
F. Guilford - Palo Alto CA, US
International Classification:
A61K031/415
A61K031/198
US Classification:
514/406000, 514/562000
Abstract:
The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as “HMG-CoA inhibitor(s)”), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The inventors propose a combination of an HMG-CoA reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying compound, particularly cystine, for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. Also contemplated is the addition of lipoic acid and compounds to maintain adequate levels of Selenium, Vitamin C and Vitamin E. Based on the clinical results of retardation, but not cure of cancer, the combination has the characteristic of sufficiently interfering with replication and apparently restoring the immune system capacity to manage cancer.

Combination And Method Using Edta, Cystine, Zinc And Selenium For Anti-Thrombin Effect And For Anti-Platelet Aggregation And Measurement Of Efficacy

US Patent:
2002018, Dec 5, 2002
Filed:
Jan 8, 2002
Appl. No.:
10/040713
Inventors:
George Kindness - Middletown OH, US
F. Guilford - Palo Alto CA, US
Brooke Schumm - Ellicott City MD, US
International Classification:
C12Q001/00
A61K033/32
A01N059/16
A61K033/04
A01N059/02
A61K031/355
US Classification:
435/004000, 424/702000, 424/641000, 514/458000
Abstract:
The invention is for the combination of EDTA, cystine, selenium, Vitamin C, Vitamin E, and zinc for anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal and for the monitoring of the response to therapy with the combination. Methods for use of the components and method for performing the monitoring are included. The combination and method are particularly efficacious for vascular deficiency ailments including atherosclerotic vascular disease, reduction of ischemic cerebal event, complications from surgical procedures including restenosis, neurogenerative disease, and erectile disfunction, and vascular deficiency resulting from etiology of sepsis and chronic infection.

Adjuvant Immune Therapy In The Treatment Of Solid Tumors Through Modulation Of Signaling Pathways Following Engagement Of Humoral And Cell Mediated Responses

US Patent:
2002018, Dec 12, 2002
Filed:
Jun 13, 2001
Appl. No.:
09/880745
Inventors:
George Kindness - Middletown OH, US
Brooke Schumm - Ellicott City MD, US
F. Guilford - Palo Alto CA, US
International Classification:
A61K045/00
A61K038/16
US Classification:
424/093700, 514/008000
Abstract:
The invention combines a novel combination with two especially important aspects: first, the invention proposes to simultaneously stimulate response in white blood cells and a patient's tumor cells with a mitogen-challenging compound, preferably a lectin, in the preferred mode the selected lectin being phytohemagglutin (“PHA”), and second, to generate heat shock protein. A method of treatment is set out. The method of manufacturing proposed utilizes a system calculated to better insure sterility and streamline production of the cytokine modulator. A method of testing in conjunction with the therapy is also claimed utilizing clinical assessment of disease activity, patient performance status, and quality of life questionnaire. Should efficacy of a treatment fall off, particularly because of mutation or adaption, the composition and method may be re- applied. The invention is not limited to humans, but is also applicable to mammals. The composition is usable as a stand-alone composition, but preferably is used in conjunction with standard therapy such as radiation, chemotherapy or surgery, particularly surgical therapy, and in conjunction with the administration of cystine, as later defined, to enhance immune system competency.

Possible Relatives

David M Schumm  Deborah A Schumm  Donald W Schumm  Dorothy T Schumm  George H Schumm  Gerald P Schumm  James D Schumm  Brooke Johnson  Brooke L Johnston  Brooke L Stanford 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.